Labrosse Julie, Morel Charlotte, Lam Thanh, Laas Enora, Feron Jean-Guillaume, Coussy Florence, Lae Marick, Reyal Fabien, Hamy Anne-Sophie
Department of Surgery, Institut Curie, 75005 Paris, France.
Department of Gynecology and Obstretrics, Hôpitaux Universitaires de Genève, 1205 Geneva, Switzerland.
Cancers (Basel). 2021 Jan 10;13(2):235. doi: 10.3390/cancers13020235.
A ductal in situ (DCIS) component is often associated with invasive breast carcinoma (BC), and its effect on response to treatment is unknown. We assessed the predictive value of the DCIS component for pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC). We analyzed a cohort of 1148 T1-3NxM0 breast cancer (BC) patients treated by NAC at Institut Curie between 2002 and 2012. The presence of a DCIS component was retrospectively recorded from both the pre-NAC biopsy pathological report and surgical specimens. We included 1148 BC patients treated by NAC for whom pre- and post-NAC data concerning the in situ component were available. DCIS was present before NAC in 19.6% of the population. Overall, 283 patients (19.4%) achieved pCR after NAC. There was no significant association between the presence of DCIS on pre-NAC biopsy and pCR. In a multivariate analysis including subtype, tumor size, grade, mitotic index, and Ki67 index, only BC subtype (luminal/TNBC/-positive) and Ki67 were significantly associated with pCR. The presence of a DCIS component on pre-NAC biopsy is not associated with pCR and does not seem to be a critical factor for predicting response to NAC.
导管原位癌（DCIS）成分常与浸润性乳腺癌（BC）相关，但其对治疗反应的影响尚不清楚。我们评估了DCIS成分对新辅助化疗（NAC）后病理完全缓解（pCR）的预测价值。我们分析了2002年至2012年期间在居里研究所接受NAC治疗的1148例T1-3NxM0乳腺癌（BC）患者队列。从NAC前活检病理报告和手术标本中回顾性记录DCIS成分的存在情况。我们纳入了1148例接受NAC治疗且有NAC前后原位成分数据的BC患者。19.6%的患者在NAC前存在DCIS。总体而言，283例患者（19.4%）在NAC后达到pCR。NAC前活检中DCIS的存在与pCR之间无显著关联。在包括亚型、肿瘤大小、分级、有丝分裂指数和Ki67指数的多因素分析中，只有BC亚型（管腔型/三阴型/HER2阳性）和Ki67与pCR显著相关。NAC前活检中DCIS成分的存在与pCR无关，似乎不是预测NAC反应的关键因素。
